Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2016

View Archived Issues

Kezar Life Sciences begins phase I study of its immunoproteasome inhibitor

Aphios obtains funding from NIAID to develop cure for HIV/AIDS

C3 may be useful as a biomarker to monitor ERT efficacy in Fabry disease

New transgenic model to assess target engagement of tau gene silencing therapies in live mice

Phase I data for CAR-modified T-cell immunotherapy in patients with non-Hodgkin's lymphoma

Azevan reports promising phase II data for SRX-246 in intermittent explosive disorder

Merck KGaA joins project to improve vaccine purification processes

FDA approves Shire's Cuvitru for primary immunodeficiency

Allele Biotechnology and Pharmaceuticals awarded SBIR grant from NHLBI

Neural Analytics receives NIH grant to develop brain diagnostic and monitoring platform

Launch of Relay Therapeutics with novel drug discovery platform focused on protein motion

Bayer and Monsanto sign definitive merger agreement

Aerie reports encouraging data from first registration trial of Roclatan

Allergan to acquire Vitae Pharmaceuticals and strengthen its dermatology product pipeline

Inhibikase Therapeutics cleared to conduct clinical studies of ABL inhibitors in Parkinson's disease

SELLAS Life Sciences enters CRADA to develop AML-MRD assay

Lenvatinib approved in E.U. for renal cell carcinoma

New gene silencing model confirms the XPO1 gene as a target for treating heart failure

KCa3.1 channel blockade shows promise as a therapeutic target in pulmonary fibrosis

FDA committee says studies of apaziquone do not show evidence of treatment effect

Bexion initiates phase I trial of BXQ-350 for advanced solid tumors

Basilea partners with Asahi Kasei Pharma for isavuconazole in Japan

Research indicates AQP1 as potential therapeutic target for pulmonary hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...